Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: SGN-15, Seattle Genetics Inc.

S Smith1

  • 1Suzanne_Smith162@hotmail.com

Current Opinion in Molecular Therapeutics
|August 11, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidental finding of endolymphatic stromal myosis during luteinizing hormone releasing hormone agonist therapy for suspected benign uterine myomata. A case report.

The Journal of reproductive medicine·1992
Same author

Immunotherapy with a tumor-infiltrating lymphocyte clone, soluble antigen, and cyclophosphamide.

Archives of surgery (Chicago, Ill. : 1960)·1992
Same author

Respiratory epithelial cell invasion by group B streptococci.

Infection and immunity·1992
Same author

Psychiatrists and their patients--confidential information in the wake of spycatcher.

The Australian and New Zealand journal of psychiatry·1992
Same author

Continuous catheter drainage of Streptococcus pneumoniae pericardial effusion.

Journal of the Royal Society of Medicine·1992
Same author

Index of suspicion. Case 1. Diagnosis: Klinefelter syndrome.

Pediatrics in review·1992

Seattle Genetics is developing SGN-15, a novel antibody-drug conjugate for cancer treatment. This therapy, licensed from Bristol-Myers Squibb, is currently advancing through Phase II clinical trials.

Area of Science:

  • Oncology
  • Biotechnology
  • Pharmacology

Background:

  • Seattle Genetics is developing SGN-15, an antibody-doxorubicin conjugate.
  • SGN-15 is licensed from Bristol-Myers Squibb (BMS) and is currently in Phase II trials.
  • BMS has utilized Enzon's technology to enhance antibody tumor penetration.

Purpose of the Study:

  • To summarize the development and licensing of SGN-15.
  • To highlight collaborations involved in SGN-15's advancement.
  • To note the ongoing clinical trial status of SGN-15.

Main Methods:

  • Review of licensing agreements and collaborations.
  • Tracking of clinical trial progression.
  • Analysis of antibody-drug conjugate technology.

Related Experiment Videos

Main Results:

  • SGN-15 is a monoclonal antibody-doxorubicin conjugate developed by Seattle Genetics.
  • The drug candidate was licensed from Bristol-Myers Squibb in April 1999.
  • BMS has engaged in R&D with Genzyme for production and with Ixsys for molecular design technology.

Conclusions:

  • SGN-15 represents a significant development in antibody-drug conjugate therapy for cancer.
  • The progression to Phase II trials indicates promising potential.
  • Strategic collaborations have been crucial for the development of SGN-15.